Competitors
| Companies | Market Cap | G | R | O | W | T | H |
|---|---|---|---|---|---|---|---|
|
Merck NYSE:MRK |
287,71 B | 7,67% | 6/6 | -21,38% | -6,39% | 13,43% | UP |
|
Novo Nordisk A/S CPSE:NOVO B |
1.056,66 B | 20,54% | 5/6 | -8,60% | 66,79% | 26,47% | DOWN |
|
Pfizer NYSE:PFE |
153,36 B | 7,82% | 4/6 | -5,31% | 22,17% | 0,15% | UP |
|
Bristol-Myers Squibb NYSE:BMY |
116,87 B | 1,77% | 5/6 | -0,30% | 1,35% | 11,52% | UP |
|
Vertex Pharmaceuticals NasdaqGS:VRTX |
113,97 B | 13,44% | 6/6 | 6,43% | -4,13% | 24,38% | UP |
|
Sanofi ENXTPA:SAN |
93,91 B | 5,21% | 5/6 | 6,94% | 18,52% | 28,58% | DOWN |
|
Takeda Pharmaceutical Company TSE:4502 |
8.946,48 B | 10,31% | 3/5 | 22,10% | -26,04% | 2,42% | UP |
|
Incyte NasdaqGS:INCY |
18,04 B | 41,79% | 5/6 | 9,11% | 30,93% | 18,08% | UP |
|
Ionis Pharmaceuticals NasdaqGS:IONS |
11,51 B | 2,79% | 2/6 | -10,58% | -166,68% | 38,49% | UP |
|
BioMarin Pharmaceutical NasdaqGS:BMRN |
10,40 B | 12,22% | 5/6 | 45,50% | 59,97% | 73,78% | DOWN |
|
PTC Therapeutics NasdaqGS:PTCT |
5,34 B | 31,02% | 5/6 | -43,33% | -60,69% | 33,25% | UP |
|
CRISPR Therapeutics NasdaqGM:CRSP |
4,46 B | 30,82% | 2/6 | 1267,38% | 52,97% | 72,30% | DOWN |
|
Agios Pharmaceuticals NasdaqGS:AGIO |
1,66 B | -20,51% | 2/6 | 69,17% | -33,16% | 30,51% | DOWN |
|
Geron NasdaqGS:GERN |
0,97 B | 225,94% | 3/5 | 18,44% | 99,15% | 164,90% | DOWN |
|
Fulcrum Therapeutics NasdaqGM:FULC |
0,45 B | 0,00% | 1/4 | 0,00% | 0,00% | 220,90% | DOWN |
|
Silence Therapeutics NasdaqGM:SLN |
0,25 B | 46,48% | 2/6 | -87,89% | 61,88% | 380,77% | DOWN |
|
Emmaus Life Sciences OTCPK:EMMA |
0,00 B | -11,68% | 2/4 | 0,00% | 0,00% | -100,00% | DOWN |
